Fact CheckerSign in

NCT05958368Active, not recruiting

Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes

The Effects of Hass Avocados on Glycemic Control in Persons With Type 2 Diabetes: A Randomized Controlled Crossover Trial

Source: ClinicalTrials.gov · Last updated 25 Sept 2026

Brief summary (registry, in English)

The objective of this study is to assess the effects of Hass Avocados on glycemic control. The investigators hypothesize that Hass Avocado consumption will reduce fasting blood sugar compared to an isocaloric amount of other fruit during controlled feeding.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
48 (actual)
First submitted
14 Jul 2023
Start date
10 Oct 2023
Primary completion date
30 Nov 2026
Lead sponsor
Pennington Biomedical Research Center
NCT number
NCT05958368

What you commit to

  • Study type: Interventional
  • Participants enrolled: 48
  • From 10 Oct 2023 to the primary completion date, 30 Nov 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Participation in a weight control program within the past 3 months or weight loss of ≥ 5 kg in the previous 3 months
  • Taking prescription or OTC weight loss medications within last 4 weeks
  • Thyroid disease for which the participant is untreated or has had treatment changed within the last 6 months. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable
  • Participation in another clinical trial within 30 days prior to enrollment

Other illness

  • History of a surgical procedure for weight loss in last 5 years (e.g. gastroplasty, gastric by-pass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve)
  • History of major surgery within three months of enrollment
  • Type 1 diabetes, insulin dependent type 2 diabetes, thiazolidinediones (including rosiglitazone and pioglitazone)
  • Unstable heart disease (an ongoing workup or treatment for a cardiac symptom such as unstable angina, coronary ischemia)
  • Presence of implanted cardiac defibrillator
  • Uncontrolled gastrointestinal disorders including chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, chronic diarrhea, or active gallbladder disease
  • Current cancer or cancer treatment, or a history of cancer or cancer treatment within the last 3 years. Persons with successfully resected non-melanoma carcinoma of the skin may be enrolled.
  • Dementia, psychiatric illness, or substance abuse that may interfere with adherence (e.g., illness that is currently unstable or resistant to first-line therapy; substance abuse in the past year)
  • Any other condition or factor which in the opinion of the study physician or investigator makes it inadvisable for the candidate to participate in the trial

Lab values

  • Renal insufficiency consisting of potassium over 5.5 (mmol/L) on a non-hemolyzed specimen, or a creatinine over 2.5 mg/dL
  • Bilirubin over 3 (mg/dL) or an albumin less than 3 (g/dL)
  • ALT \> 3 (IU/L) times the upper limit of normal (normal range is 7-56)
  • Evidence of more than 1 severe hypoglycemic event (episode requiring emergency medical services) in the past 12 months, unless the participant's treating physician provides written clearance for participation.

Other

  • Not willing or unable to consume study foods including avocados
  • Those on higher doses of diuretics (furosemide 40mg or higher or comparable)
  • Blood pressure ≥180/100 mm Hg. If a potential participant has a BP above the inclusion criteria it is acceptable to re-test this potential participant within one week of the original test.
  • Women who are pregnant, lactating, trying to become pregnant or unwilling to use an effective means of birth control
  • Currently consuming \>14 alcoholic drinks (1 drink = 12 fl oz beer, 4 fl oz wine or 1.5 fl oz liquor) per week and unwilling to stop intake during study participation

Who the study is looking for

  • Participant reported diagnosis of Type 2 diabetes
  • HbA1c between 5.7%-11% (inclusive) and / or fasting blood glucose of ≥ 100 mg/dL
  • BMI 27-50 kg/m2 (inclusive)
  • Age range - 18 - 65 years (inclusive)
  • On stable regimen of all medications (including diabetes) for at least 3 months (brief regimens of medications such as antibiotics, steroids, etc. are permitted)
  • Willing to follow all requirements of study protocol including blood draws
  • Under the care of a physician who will be responsible for managing the subject's diabetes
  • Willing to give release to provide their treating MD with information about the trial

Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Pennington Biomedical Research Center
Coordinator of this site? Confirm its status
Baton RougeUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.